(Q80978609)
Statements
Rosiglitazone produces a greater reduction in circulating platelet activity compared with gliclazide in patients with type 2 diabetes mellitus--an effect probably mediated by direct platelet PPARgamma activation (English)
Khanolkar MP
Morris RH
Thomas AW
Bolusani H
Roberts AW
Geen J
Jackson SK